Abstract
No public abstract is available from the verified source records.
Michael Ayers, Christopher M. Kramer
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)
2014
Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe)
10.1161/circulationaha.117.033200 · 2018
Hypertrophic cardiomyopathy: a systematic review
10.1001/jama.287.10.1308 · 2002
Hypertrophic cardiomyopathy and sudden cardiac death
10.4330/wjc.v2.i9.289 · 2010
Hypertrophic cardiomyopathy-related sudden cardiac death in young people in ontario
10.1161/circulationaha.119.040271 · 2019
Vigorous exercise in patients with hypertrophic cardiomyopathy
10.1001/jamacardio.2023.1042 · 2023
Return-to-play for elite athletes with genetic heart diseases predisposing to sudden cardiac death
10.1016/j.jacc.2023.05.059 · 2023
The molecular genetic basis for hypertrophic cardiomyopathy
10.1006/jmcc.2001.1340 · 2001
Familial cardiomegaly
10.1136/hrt.11.1.68 · 1949
Asymmetrical hypertrophy of the heart in young adults
10.1136/hrt.20.1.1 · 1958
Clinical and mechanistic insights into the genetics of cardiomyopathy
10.1016/j.jacc.2016.08.079 · 2016
Hypertrophic cardiomyopathy: an overview of genetics and management
10.3390/biom9120878 · 2019
Time to think differently about sarcomere-negative hypertrophic cardiomyopathy
10.1161/circulationaha.121.053527 · 2021
Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry
10.1016/j.jacc.2019.08.1057 · 2019
Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy
10.1161/circulationaha.119.042339 · 2020
Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis
10.1161/circulationaha.120.052359 · 2021
2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines
2020
Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance
10.1016/j.jacc.2009.05.006 · 2009
Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy
10.1016/j.jacc.2008.04.047 · 2008
Discrepant measurements of maximal left ventricular wall thickness between cardiac magnetic resonance imaging and echocardiography in patients with hypertrophic cardiomyopathy
10.1161/circimaging.117.006309 · 2017
Comparison of maximal wall thickness in hypertrophic cardiomyopathy differs between magnetic resonance imaging and transthoracic echocardiography
10.1016/j.amjcard.2016.11.010 · 2017
Prognostic significance of anterior mitral valve leaflet length in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes
10.1007/s40477-018-0302-9 · 2018
High normal blood pressure and left ventricular hypertrophy echocardiographic findings from the PAMELA population
10.1161/hypertensionaha.118.12114 · 2019
Hypertrophic cardiomyopathy: clinical update
10.1016/j.jchf.2018.02.010 · 2018
Left ventricular outflow tract obstruction caused by massive mitral annular calcification in a patient with hypertensive heart disease
2015
Athletic cardiac remodeling in US professional basketball players
10.1001/jamacardio.2015.0252 · 2016
Prevalence and pattern of cardiovascular magnetic resonance late gadolinium enhancement in highly trained endurance athletes
10.1186/s12968-020-00660-w · 2020
Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy
10.1016/j.jcmg.2011.11.021 · 2012
Assessing myocardial extracellular volume by T1 mapping to distinguish hypertrophic cardiomyopathy from athlete’s heart
10.1016/j.jacc.2016.02.054 · 2016
Impact of a center of excellence in confirming or excluding a diagnosis of hypertrophic cardiomyopathy
10.1016/j.amjcard.2023.09.040 · 2023
Magnetic resonance in transthyretin cardiac amyloidosis
10.1016/j.jacc.2017.05.053 · 2017
Cardiomyopathy in Friedreich’s ataxia-assessment by cardiac MRI
10.1002/mds.21590 · 2007
Friedreich’s ataxia presenting as cardiac disease
10.1007/bf02265406 · 1985
Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes
10.1038/gim.2017.121 · 2018
Evaluation of myocardial iron overload by T2∗ cardiovascular magnetic resonance imaging
2005
Cardiovascular magnetic resonance findings in patients with PRKAG2 gene mutations
10.1186/s12968-015-0192-3 · 2015
Clinical spectrum of PRKAG2 syndrome
10.1161/circep.115.003121 · 2016
Cardiac MRI in fabry disease
2022
Fabry disease therapy: state-of-the-Art and current challenges
10.3390/ijms22010206 · 2020
Cardiovascular magnetic resonance findings in Danon disease: a case series of a family
2023
Phenotyping hypertrophic cardiomyopathy using cardiac diffusion magnetic resonance imaging: the relationship between microvascular dysfunction and microstructural changes
10.1093/ehjci/jeab210 · doi-reference
Myocardial extracellular volume fraction adds prognostic information beyond myocardial replacement fibrosis
10.1161/circimaging.119.009535 · doi-reference
Speckle tracking imaging in hypertrophic cardiomyopathy
10.1007/s00059-017-4653-3 · doi-reference
Three-dimensional left ventricular deformation in hypertrophic cardiomyopathy
10.1161/01.cir.90.2.854 · doi-reference
Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe registry
10.1161/circulationaha.119.044366 · doi-reference
Different mechanisms of mitral regurgitation in hypertrophic cardiomyopathy: A clinical case and literature review
10.3389/fcvm.2022.1020054 · doi-reference
The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context
10.1016/j.jacc.2016.01.071 · doi-reference
Mechanism of left ventricular outlfow obstruction in patients with obstructive asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis)
10.1016/0002-9149(75)90025-9 · doi-reference
Toward replacing late gadolinium enhancement with artificial intelligence virtual native enhancement for gadolinium-free cardiovascular magnetic resonance tissue characterization in hypertrophic cardiomyopathy
10.1161/circulationaha.121.054432 · doi-reference
Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications
10.1093/ehjci/jey135 · doi-reference
Prognostic value of LGE-CMR in HCM: a meta-analysis
10.1016/j.jcmg.2016.02.031 · doi-reference
Diagnostic and prognostic role of late gadolinium enhancement in cardiomyopathies
10.1093/eurheartjsupp/suad015 · doi-reference
Quantitative late gadolinium enhancement cardiac magnetic resonance and sudden death in hypertrophic cardiomyopathy: a meta-analysis
10.1016/j.jcmg.2023.07.005 · doi-reference
Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy
10.1161/circulationaha.113.007094 · doi-reference
Late Gadolinium enhancement in hypertrophic cardiomyopathy: is there more to it than size?
10.1016/j.jcmg.2023.11.013 · doi-reference
Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR
10.1016/j.jcmg.2012.09.018 · doi-reference
Myocardial fibrosis in hypertrophic cardiomyopathy: a perspective from fibroblasts
10.3390/ijms241914845 · doi-reference
Right ventricular involvement in hypertrophic cardiomyopathy
10.1016/j.amjcard.2007.05.061 · doi-reference
Diagnosis and clinical implication of left ventricular aneurysm in hypertrophic cardiomyopathy
10.3390/diagnostics13111848 · doi-reference
Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy
10.1161/circulationaha.108.781401 · doi-reference
Apical hypertrophic cardiomyopathy: the variant less known
10.1161/jaha.119.015294 · doi-reference
Fabry disease therapy: state-of-the-Art and current challenges
10.3390/ijms22010206 · doi-reference
Clinical spectrum of PRKAG2 syndrome
10.1161/circep.115.003121 · doi-reference
Cardiovascular magnetic resonance findings in patients with PRKAG2 gene mutations
10.1186/s12968-015-0192-3 · doi-reference
Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes
10.1038/gim.2017.121 · doi-reference
Friedreich’s ataxia presenting as cardiac disease
10.1007/bf02265406 · doi-reference
Cardiomyopathy in Friedreich’s ataxia-assessment by cardiac MRI
10.1002/mds.21590 · doi-reference
Magnetic resonance in transthyretin cardiac amyloidosis
10.1016/j.jacc.2017.05.053 · doi-reference
Impact of a center of excellence in confirming or excluding a diagnosis of hypertrophic cardiomyopathy
10.1016/j.amjcard.2023.09.040 · doi-reference
Assessing myocardial extracellular volume by T1 mapping to distinguish hypertrophic cardiomyopathy from athlete’s heart
10.1016/j.jacc.2016.02.054 · doi-reference
Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy
10.1016/j.jcmg.2011.11.021 · doi-reference
Prevalence and pattern of cardiovascular magnetic resonance late gadolinium enhancement in highly trained endurance athletes
10.1186/s12968-020-00660-w · doi-reference
Athletic cardiac remodeling in US professional basketball players
10.1001/jamacardio.2015.0252 · doi-reference
Hypertrophic cardiomyopathy: clinical update
10.1016/j.jchf.2018.02.010 · doi-reference
High normal blood pressure and left ventricular hypertrophy echocardiographic findings from the PAMELA population
10.1161/hypertensionaha.118.12114 · doi-reference
Prognostic significance of anterior mitral valve leaflet length in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes
10.1007/s40477-018-0302-9 · doi-reference
Comparison of maximal wall thickness in hypertrophic cardiomyopathy differs between magnetic resonance imaging and transthoracic echocardiography
10.1016/j.amjcard.2016.11.010 · doi-reference
Discrepant measurements of maximal left ventricular wall thickness between cardiac magnetic resonance imaging and echocardiography in patients with hypertrophic cardiomyopathy
10.1161/circimaging.117.006309 · doi-reference
Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy
10.1016/j.jacc.2008.04.047 · doi-reference
Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance
10.1016/j.jacc.2009.05.006 · doi-reference